In a regulatory filing, Regeneron EVP and General Counsel Joseph LaRosa disclosed the sale of 1,000 common shares of the company on February 7 at a price of $950 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- Regeneron Announces Investor Conference Presentations
- Regeneron Pharmaceuticals Is Worried About This – Should You Be Worried Too?
- Regeneron price target raised to $1,135 from $1,045 at Truist
- Regeneron price target raised to $1,082 from $1,055 at BMO Capital
- Regeneron price target raised to $1,110 from $1,076 at RBC Capital